Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 6/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009231 | 0.84 | TAS1R3 (0.43) | HSD17B10ABL1BCRPROKR1 | |
| SCHEMBL30009093 | 0.82 | GAA (0.38) | HSD17B10PROKR1 | |
| SCHEMBL30009435 | 0.81 | PROKR1 (0.49) | HSD17B10PROKR1 | |
| SCHEMBL20811676 | 0.74 | SMN1; SMN2 (0.43) | JAK1SMN1; SMN2LMNAHSD17B10ALDH1A1 | |
| SCHEMBL22221054 | 0.71 | CTSK (0.41) | JAK1SMN1; SMN2LMNAHSD17B10ALDH1A1 | |
| SCHEMBL30009910 | 0.71 | JAK1 (0.40) | JAK1HSD17B10ALDH1A1PROKR1 | |
| SCHEMBL30009010 | 0.70 | LMNA (0.45) | JAK1LMNAALDH1A1 | |
| SCHEMBL30009325 | 0.70 | HPGD (0.66) | SMN1; SMN2HSD17B10ALDH1A1TSHR | |
| SCHEMBL22221304 | 0.70 | SMN1; SMN2 (0.42) | JAK1SMN1; SMN2LMNAHSD17B10ALDH1A1 | |
| SCHEMBL16652197 | 0.69 | HDAC4 (0.41) | JAK1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | JAK1 83/4885SMN1; SMN2 2457/4885LMNA 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.